Share on StockTwits
 

Equities researchers at UBS AG assumed coverage on shares of AstraZeneca (NYSE:AZN) in a research report issued on Thursday, American Banking and Market News reports. The firm set a “buy” rating on the stock.

AstraZeneca (NYSE:AZN) traded up 0.89% on Thursday, hitting $59.04. The stock had a trading volume of 742,855 shares. AstraZeneca has a 52-week low of $44.46 and a 52-week high of $59.67. The stock has a 50-day moving average of $57.42 and a 200-day moving average of $52.33. The company has a market cap of $73.977 billion and a P/E ratio of 15.78.

AstraZeneca (NYSE:AZN) last announced its earnings results on Thursday, October 31st. The company reported $1.21 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.27 by $0.06. The company had revenue of $6.25 billion for the quarter, compared to the consensus estimate of $6.45 billion. During the same quarter in the prior year, the company posted $1.51 earnings per share. The company’s quarterly revenue was down 6.5% on a year-over-year basis. On average, analysts predict that AstraZeneca will post $5.07 earnings per share for the current fiscal year.

A number of other firms have also recently commented on AZN. Analysts at Jefferies Group upgraded shares of AstraZeneca from an “underperform” rating to a “hold” rating in a research note to investors on Thursday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Monday. They now have a $62.00 price target on the stock. Finally, analysts at Bryan Garnier & Cie downgraded shares of AstraZeneca from a “buy” rating to a “neutral” rating in a research note to investors on Friday, December 20th. Five research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $56.80.

AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.